IL6 and COVID-19: IL-6, a key driver of hyperinflammation, has been targeted with IL-6 inhibitors such as tocilizumab and sarilumab, which have demonstrated efficacy in acute COVID-19 but may also have a role in managing persistent post-COVID-19 inflammatory syndromes [69,70].